NO20021476L - Pharmaceutical borer formulation - Google Patents
Pharmaceutical borer formulationInfo
- Publication number
- NO20021476L NO20021476L NO20021476A NO20021476A NO20021476L NO 20021476 L NO20021476 L NO 20021476L NO 20021476 A NO20021476 A NO 20021476A NO 20021476 A NO20021476 A NO 20021476A NO 20021476 L NO20021476 L NO 20021476L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical
- borer
- formulation
- fatty acid
- acid esters
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Det er beskrevet bærersystemer nyttige for fremstilling av farmasøytiske formuleringer, idet systemene omfatter, i vektprosentandeler, fra omtrent 1 % til omtrent 20 %, fortrinnsvis fra omtrent 5 % til omtrent 12 %, av en overflateaktive middelkomponent; fra omtrent 55 % til omtrent 93 %, fortrinnsvis fra omtrent 60 % til omtrent 85, av en komponent av en eller flere polyetylenglkoler (PEG); og fra omtrent 1 % til omtrent 25 %, fortrinnsvis fra omtrent 5 % til omtrent 15 %, av "en eller flere sukrosefettsyrestere eller polybinylpyrrolidon (PVP) med en K.-verdi på mellom omtrent 15 og omtrent 90, fortrinnsvis med en K-verdi på fra omtrent 16 til omtrent 18, mest foretrukket omtrent 17, som definert i USP/NF, eller en kombina- jon av en eller flere sukrosefettsyreestere eller PVP, og eventuelt en eller flere farmasøytisk akseptable konserveringsmidler, slik som BHA, BHT, askorbyl- palmitat eller benzylalkohol.Carrier systems are disclosed useful in the preparation of pharmaceutical formulations, the systems comprising, in weight percentages, from about 1% to about 20%, preferably from about 5% to about 12%, of a surfactant component; from about 55% to about 93%, preferably from about 60% to about 85, of a component of one or more polyethylene glycol (PEG); and from about 1% to about 25%, preferably from about 5% to about 15%, of "one or more sucrose fatty acid esters or polybinylpyrrolidone (PVP) having a K value of between about 15 and about 90, preferably with a K values of from about 16 to about 18, most preferably about 17, as defined in USP / NF, or a combination of one or more sucrose fatty acid esters or PVPs, and optionally one or more pharmaceutically acceptable preservatives, such as BHA, BHT, ascorbyl - palmitate or benzyl alcohol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40616499A | 1999-09-27 | 1999-09-27 | |
| PCT/US2000/026381 WO2001022942A1 (en) | 1999-09-27 | 2000-09-26 | Pharmaceutical carrier formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20021476D0 NO20021476D0 (en) | 2002-03-25 |
| NO20021476L true NO20021476L (en) | 2002-04-16 |
Family
ID=23606801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021476A NO20021476L (en) | 1999-09-27 | 2002-03-25 | Pharmaceutical borer formulation |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1216029A1 (en) |
| JP (1) | JP2003510267A (en) |
| KR (1) | KR20020064289A (en) |
| CN (1) | CN1399542A (en) |
| AR (1) | AR025867A1 (en) |
| AU (1) | AU7716100A (en) |
| BR (1) | BR0014308A (en) |
| CA (1) | CA2388471A1 (en) |
| CZ (1) | CZ20021082A3 (en) |
| EA (1) | EA200200415A1 (en) |
| HK (1) | HK1044485A1 (en) |
| HU (1) | HUP0202652A3 (en) |
| IL (1) | IL148543A0 (en) |
| MX (1) | MXPA02003190A (en) |
| NO (1) | NO20021476L (en) |
| PL (1) | PL354331A1 (en) |
| WO (1) | WO2001022942A1 (en) |
| ZA (1) | ZA200203311B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| JPWO2004073692A1 (en) * | 2003-02-18 | 2006-06-01 | 山下 伸二 | Hard capsule of poorly water-soluble drug |
| CN100342856C (en) * | 2003-04-10 | 2007-10-17 | 上海医药工业研究院 | Composition of danazol semisolid skeleton preparation |
| JP5406529B2 (en) | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス， インコーポレイテッド | Dual controlled release matrix system based on lipophilic vehicle as capsule filler |
| EP1959935A2 (en) * | 2005-10-26 | 2008-08-27 | Banner Pharmacaps Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
| TW200826932A (en) * | 2006-10-31 | 2008-07-01 | Wyeth Corp | Semi-solid formulations of phospholipase enzyme inhibitors |
| ES2944116T3 (en) * | 2017-12-20 | 2023-06-19 | Firmenich & Cie | Oral care compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3636123A1 (en) * | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE |
| WO1995022331A1 (en) * | 1994-02-18 | 1995-08-24 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
| CA2318128C (en) * | 1998-01-20 | 2008-10-14 | Applied Analytical Industries, Inc. | Oral liquid compositions |
-
2000
- 2000-09-26 CN CN00816307A patent/CN1399542A/en active Pending
- 2000-09-26 KR KR1020027003934A patent/KR20020064289A/en not_active Application Discontinuation
- 2000-09-26 CZ CZ20021082A patent/CZ20021082A3/en unknown
- 2000-09-26 AU AU77161/00A patent/AU7716100A/en not_active Abandoned
- 2000-09-26 WO PCT/US2000/026381 patent/WO2001022942A1/en not_active Application Discontinuation
- 2000-09-26 IL IL14854300A patent/IL148543A0/en unknown
- 2000-09-26 HU HU0202652A patent/HUP0202652A3/en unknown
- 2000-09-26 CA CA002388471A patent/CA2388471A1/en not_active Abandoned
- 2000-09-26 EP EP00966880A patent/EP1216029A1/en not_active Withdrawn
- 2000-09-26 JP JP2001526154A patent/JP2003510267A/en active Pending
- 2000-09-26 BR BR0014308-1A patent/BR0014308A/en not_active Application Discontinuation
- 2000-09-26 PL PL00354331A patent/PL354331A1/en not_active Application Discontinuation
- 2000-09-26 AR ARP000105037A patent/AR025867A1/en unknown
- 2000-09-26 MX MXPA02003190A patent/MXPA02003190A/en unknown
- 2000-09-26 EA EA200200415A patent/EA200200415A1/en unknown
-
2002
- 2002-03-25 NO NO20021476A patent/NO20021476L/en not_active Application Discontinuation
- 2002-04-25 ZA ZA200203311A patent/ZA200203311B/en unknown
- 2002-08-23 HK HK02106196.7A patent/HK1044485A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0014308A (en) | 2002-05-21 |
| ZA200203311B (en) | 2003-12-31 |
| EP1216029A1 (en) | 2002-06-26 |
| PL354331A1 (en) | 2004-01-12 |
| HUP0202652A3 (en) | 2004-06-28 |
| CN1399542A (en) | 2003-02-26 |
| IL148543A0 (en) | 2002-09-12 |
| KR20020064289A (en) | 2002-08-07 |
| AR025867A1 (en) | 2002-12-18 |
| CZ20021082A3 (en) | 2002-06-12 |
| WO2001022942A1 (en) | 2001-04-05 |
| MXPA02003190A (en) | 2002-09-30 |
| EA200200415A1 (en) | 2002-10-31 |
| CA2388471A1 (en) | 2001-04-05 |
| AU7716100A (en) | 2001-04-30 |
| HUP0202652A2 (en) | 2004-05-28 |
| JP2003510267A (en) | 2003-03-18 |
| NO20021476D0 (en) | 2002-03-25 |
| HK1044485A1 (en) | 2002-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6946120B2 (en) | Pharmaceutical composition | |
| CA2282513A1 (en) | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations | |
| CY1114631T1 (en) | PHARMACEUTICAL FORMS OF ECHINOCANDIN Containing surfactants that form a micelle | |
| IE871335L (en) | Steroid formulations. | |
| CA2081068A1 (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of .alpha.-d-neuraminic acid | |
| ES2110377T1 (en) | GALLENIC FORMULATION OF PHENOFIBRATE AND APPLICATION OF THE SAME. | |
| EP0215423A3 (en) | Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation | |
| RU2003132426A (en) | PHARMACEUTICAL SOLUTION OF ARIPIPRAZOL FOR ORAL USE | |
| WO1998020872B1 (en) | Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections | |
| CA2337745A1 (en) | Human growth hormone aqueous formulation | |
| PT918507E (en) | FORMULATIONS IN AEROSOL | |
| MX9204382A (en) | COMPOSITIONS | |
| NO20021476L (en) | Pharmaceutical borer formulation | |
| EP1886691A3 (en) | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug | |
| CA2216277A1 (en) | Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance | |
| NO950134L (en) | Formulations for orally administered pharmaceutical agents | |
| PE20030545A1 (en) | RIBAVIRIN SYRUP FORMULATIONS | |
| WO2001022969A3 (en) | Vasopressin agonist formulation and process | |
| JP2003526680A5 (en) | ||
| EP0056681A3 (en) | Levonantradol and n-methyllevonantradol formulations | |
| NO20021475L (en) | Vasopressin antagonist, formulation and method | |
| WO2001003774A3 (en) | Pharmaceutical composition for the treatment of calcification | |
| WO2002015866A3 (en) | USE OF CYCLIC 2,4-DIPHOSPHOGLYCERATES (cDGP) AND/OR DERIVATIVES THEREOF IN COSMETIC AND DERMATOLOGICAL FORMULATIONS | |
| WO2000051603A3 (en) | Compositions of remifentanil | |
| TR201708243A2 (en) | PHARMACEUTICAL SPRAY FORMULATION CONTAINING TADALAFIL AND ANTISEPTIC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |